Available online 16 February 2018 The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is de-regulated in a variety of cancers due to mutations in receptor tyrosine kinases (RTKs), negative regulators of RAS (such as NF1) and core pathway components themselves (RAS, BRAF, CRAF, MEK1 or MEK2). This has driven the development of a variety of pharmaceutical agents to inhibit RAF-MEK1/2-ERK1/2 signalling in cancer and both RAF and MEK inhibitors are now approved and used in the clinic. There is now much interest in targeting at the level of ERK1/2 for a variety of reasons. First, since the pathway is linear from RAF-to-MEK-to-ERK then ERK1/2 are validated as targets per se. Second, innate resistance to RAF or MEK inhibitors involves relief of negative feedback and pathway re-activation with all signalling going through ERK1/2, validating the use of ERK inhibitors with RAF or MEK inhibitors as an up-front combination. Third, long-term acquired resistance to RAF or MEK inhibitors involves a variety of mechanisms (KRAS or BRAF amplification, MEK mutation, etc.) which re-instate ERK activity, validating the use of ERK inhibitors to forestall acquired resistance to RAF or MEK inhibitors. The first potent highly selective ERK1/2 inhibitors have now been developed and are entering clinical trials. They have one of three discrete mechanisms of actioncatalytic, "dual mechanism" or covalent -which could have profound consequences for how cells respond and adapt. In this review we describe the validation of ERK1/2 as anti-cancer drug targets, consider the mechanism of action of new ERK1/2 inhibitors and how this may impact on their efficacy, anticipate factors that will determine how tumour cells respond and adapt to ERK1/2 inhibitors and consider ERK1/2 inhibitor drug combinations.
Introduction
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is activated by a range of extracellular stimuli including growth and differentiation factors, cytokines, hormones and neuropeptides acting through their cognate receptors (receptor tyrosine kinases, cytokine receptors, G-protein coupled receptors, etc). This pathway is perhaps best known for its prominent role in controlling gene expression (Nabet et al., 2015; Yang, Sharrocks, and Whitmarsh, 2013) . Activation of the terminal kinases in the cascade, ERK1 and ERK2, results in their accumulation in the nucleus where they phosphorylate various sequencespecific transcription factors to stimulate or repress gene expression. In this way activation of the ERK1/2 pathway can promote a range of cellular responses; notably, ERK1/2 signalling promotes cell cycle progression and cell division but can also drive cell cycle exit, differentiation and irreversible cell senescence (Meloche and Pouysségur, 2007) . These opposing cell fates are made possible by pathway properties and cellular context; for example, the magnitude and duration of ERK1/2 activation, which is determined by feedback controls, can dictate whether a cell proliferates or undergoes cell cycle arrest (Blüthgen and Legewie, 2008) whilst the consequences of ERK1/2 signalling may also be determined by the activation of coincident parallel signalling pathways (Mendoza, Er, and Blenis, 2011) . ERK1/2 signalling is by no means confined to the nucleus and ERK1/2 can also target substrates outside the nucleus to control metabolism and cell survival (Cook, Stuart, Gilley, and Sale, 2017) . Indeed, many aspects of cell physiology are regulated by ERK1/2 signalling, from the earliest cell lineage choices during development to decisions to die or survive.
The ERK1/2 signalling pathway has attracted particular attention because it is deregulated in a wide variety of cancers due to activating mutations in growth factor receptors and core pathway components, most notably RAS and BRAF (Montagut and Settleman, 2009 ). This has driven the development of a variety of pharmaceutical agents to inhibit RAF-MEK1/2-ERK1/2 signalling in cancer and both RAF and MEK inhibitors (RAFi, MEKi) are now approved and used in the clinic (Caunt, Sale, Smith, and Cook, 2015; Holderfield, Deuker, McCormick, and McMahon, 2014) . There is now much interest in targeting the pathway at the level of the terminal kinases, ERK1 and ERK2 (ERK1/2). ERK1/2 inhibitors (ERKi) will likely be used in combination to target tumour cells that are refractory to RAFi or MEKi monotherapy or to overcome or forestall acquired resistance to RAFi or MEKi. The first potent and highly selective ERKi have now been developed and are entering clinical trials. In this article we review the validation of ERK1/2 as anti-cancer drug targets, consider the mechanism of action of new ERKis and how this may impact on their efficacy, consider ERKi drug combinations and anticipate factors that will determine how tumour cells respond and adapt to ERKis.
The ERK1/2 signalling pathway
The core ERK1/2 signalling pathway is a three-tier hierarchical protein kinase cascade (Fig. 1 ). ERK1/2 exemplify a family of mitogenactivated protein kinases (MAPKs) which are activated by MAPK Kinases (MAPKKs) which are in turn activated MAPKKKs (Cargnello and Roux, 2011) . Like most protein kinases ERK1/2 are synthesised in cells as inactivate zymogens. Activation requires phosphorylation of critical threonine and tyrosine residues in the T-E-Y motif found in the kinase activation loop; T-E-Y phosphorylation has the effect of rearranging the active site to allow the correct alignment of ATP and substrate for catalysis. Phosphorylation of the ERK1/2 T-E-Y motif is catalysed by the dual-specificity protein kinases MEK1 or MEK2 (the MAPKKs), which phosphorylate first the tyrosine and then the threonine in a processive manner (Aoki, Yamada, Kunida, Yasuda, and Matsuda, 2011) . MEK1/2 are themselves activated by activation loop phosphorylation at conserved serine residues; this is catalysed by one of several different MAPKKKs including the three RAF protein kinases (ARAF, BRAF and CRAF) . Growth factors activate the ERK1/2 pathway by first activating the RAS proteins, small monomeric GTPases that are tethered on the inner leaflet of the plasma membrane and act as binary switches (Karnoub and Weinberg, 2008) . Binding of growth factors to their receptors results in the recruitment of guanine nucleotide exchange factors such as Son-of-Sevenless (SOS) to the plasma membrane where they promote the dissociation of GDP from RAS proteins; the large molar excess of GTP over GDP in cells ensures that GDP is replaced by GTP which switches RAS into its active conformation. RAS-GTP then binds to RAF proteins forming active homo or heterodimers at the plasma membrane, which then phosphorylate MEK1/2, which in turn activate ERK1/2. Whilst the core pathway is frequently represented as a simple linear RAF-MEK1/2-ERK1/2 cascade, efficient signal transmission is dependent on various scaffold proteins, which bring the component kinases together and also serve to insulate the pathway from cross talk by other kinases (Good, Zalatan, and Lim, 2011) . In addition to scaffolds, signalling fidelity is made possible by distinct kinase-substrate interactions. For example, ERK1/2 are proline-directed protein kinases, phosphorylating substrates at S/T-P motifs (Ünal, Uhlitz, and Blüthgen, 2017) ; such motifs are found in thousands of proteins that are not ERK1/2 substrates. Rather, ERK1/2 are directed to phosphorylate bona fide substrates by the presence of discrete kinase docking domains that are distinct from the S/T-P phosphoacceptor site (Bardwell, 2006; Cargnello and Roux, 2011) .
All reported mammalian cells express two canonical ERK proteins, ERK1 and ERK2, encoded by distinct genes. ERK1 and ERK2 are 84% identical at the amino acid level; in the case of the human proteins ERK1 exhibits a 17 amino acid N-terminal extension and 2 extra amino acids at the C-terminus, making it larger than ERK2. Gene disruption of erk1 or erk2 in mice has revealed striking phenotypic differences; erk1−/− mice live and reproduce normally whereas erk2 disruption causes early embryonic lethality (reviewed in (Buscà, Pouysségur, and Lenormand, 2016) . Numerous studies have sought to define functional differences between ERK1 and ERK2 that might account for these phenotypic differences. Indeed, any such differences would be a very important consideration in the design or search for ERK inhibitors. However, very few rigorous studies have reported function differences between ERK1 and ERK2 and the emerging consensus is that the two enzymes are functionally redundant, with differences in mouse knockout phenotype reflecting differences in the abundance of ERK1 and ERK2. Studies of the mouse erk1 and erk2 proximal promoters suggest that the difference in expression is in part due to the erk2 promoter being stronger than the erk1 promoter (Buscà et al., 2015) . Finally, mice lacking erk2 live and reproduce normally when erk1 is ubiquitously expressed from the chicken β-actin promoter (Frémin, Saba-El-Leil, Lévesque, Ang, and Meloche, 2015) . These mice exhibited apparently normal ERK signalling suggesting that the differences in erk1 and erk2 knockout phenotype simply reflect the different contributions each isoform makes to global ERK activity (Buscà et al., 2016) .
MEK1/2-catalysed phosphorylation results in a significant fraction of ERK1/2 entering the nucleus (Lidke et al., 2010) where it can bind to and phosphorylate transcriptional regulators to control gene transcription; indeed, this is arguably the classic paradigm for ERK1/2 signalling (Fig. 1 ). ERK1/2 phosphorylate a variety of sequence-specific transcription factors, including many members of ETS and AP-1 families (O'Donnell, Odrowaz, and Sharrocks, 2012) . In many cases these phosphorylation events promote transcription, through activation of transcriptional activation domains (TADs) or stabilisation of the relevant transcription factor; in other cases ERK1/2 phosphorylation represses transcription. As a result the ERK1/2 signaling is a major pathway by which growth factors, cytokines and hormones control gene expression (Schulze, Lehmann, Jefferies, McMahon, and Downward, 2001 ). However, ERK1/2 signalling is not confined to the nucleus and ERK1/2 can also target substrates outside the nucleus to control metabolism, mitochondrial fission and cell survival (Balmanno and Cook, 2008; Cook et al., 2017) . In this way the ERK1/2 pathway serves as a master regulator of cell fate. Indeed, ERK1/2 signalling is essential for both human and mouse embryonic stem cell maintenance and self-renewal and the maintenance of ESC genome stability (Chen et al., 2015) , highlighting a critical role for ERK1/2 signalling in the earliest cell fate decisions.
Given the role of ERK1/2 signalling in control of cell fates it comes as no surprise that the pathway is regulated by a complex array of homeostatic negative feedback controls that fine-tune pathway output. These can broadly be divided into those that are rapid and direct, operating on the minutes timescale and proceed through pre-existing components (shown in red in Fig. 1 ), and those that are slower in onset, depend on new protein synthesis and operate on the hours timescale (shown in green in Fig. 1 ). Rapid direct feedback mechanisms involve direct inhibitory phosphorylation of upstream pathway components by ERK1/2 or by ERK1/2-dependent protein kinases such as RSK. Perhaps the best examples of this are the ERK1/2 catalysed phosphorylation of CRAF (Dougherty et al., 2005) , BRAF (Ritt, Monson, Specht, and Morrison, 2010) and MEK1 (Eblen et al., 2004) , which inhibits phosphorylation of MEK by the RAF proteins and the phosphorylation of ERK1/2 by MEK1. The net effect is that ERK1/2 activation propagates a negative feedback loop that limits its own activation, whereas loss of ERK activity (for example, by treatment with a RAF or MEK inhibitor) inhibits these feedback loops, thereby activating RAF, MEK and ERK1/2 and allowing the pathway to adapt to perturbations (Sturm et al., 2010) . Slower feedback loops that confer regulation in the longer term involve the de novo expression of the dual-specificity phosphatases (DUSPs, also known as MAP kinase phosphatases or MKPs) and the Sprouty (SPRY) proteins. The DUSPs inactivate ERK1/2 by dephosphorylating the pT-E-pY motif, providing a temporally delayed ERK-driven feedback loop that is dependent upon ERK-dependent gene expression and so "reports" on delivery of the ERK1/2 signal to nuclear targets (Kidger and Keyse, 2016) . In turn, different DUSPs function in different locations allowing spatial regulation of ERK1/2 output; for example, DUSP5 resides within the nucleus whilst DUSP6 is found in the cytoplasm. SPRY proteins inhibit ERK signalling at the level of RTKs, SOS and by interfering with the RAF catalytic domain (MasoumiMoghaddam, Amini, and Morris, 2014) .
3. Validation of the ERK1/2 pathway and ERK1/2 as targets in cancer RAS proteins are mutated at high frequency in human cancer (Bos, 1989) . 20-30% of all human cancers have RAS mutations whilst in some diseases the incidence is especially high; for example 80-90% of pancreatic ductal adenocarcinomas have activating mutations in KRAS (Bos, 1989; Karnoub and Weinberg, 2008) . These mutations (typically at codons 12, 13 or 61) render the RAS proteins resistant to the activity of GTPase-activating proteins (RAS-GAPs) (Martin et al., 1990; Trahey and McCormick, 1987) , which normally terminate RAS signalling by accelerating their otherwise modest GTPase activity. As a result mutant RAS proteins accumulate in their active GTP-bound state in the absence of an inductive signal, thereby driving inappropriate cell proliferation and survival. The discovery of the RAF-MEK-ERK1/2 signalling cascade as the first effector pathway of the RAS proteins Crews, Alessandrini, and Erikson, 1992; Howe et al., 1992; Warne, Vician, and Downward, 1993; Karnoub and Weinberg, 2008) immediately prompted interest from the pharmaceutical sector and quickly led to the discovery of PD98059, an allosteric inhibitor of MEK1/2, as the first selective pathway inhibitor (Dudley, Pang, Decker, Fig. 1 . The RAF-MEK1/2-ERK1/2 cascade. A simplified representation of the RAS-regulated RAF-MEK1/2-ERK1/2 signalling cascade. Activated growth factor receptors recruit the guanine nucleotide exchange factor SOS (son of sevenless), to induce the release of GDP from RAS. This enables the binding of GTP, activating RAS. RAS-GTP promotes the dimerisation and activation of the RAF kinases (ARAF, BRAF and CRAF), which phosphorylate and activate MEK1 and MEK2 (MEK1/2), which in turn phosphorylate and activate the terminal kinases ERK1 and ERK2 (ERK1/2). Phosphorylation of ERK1/2 promotes their nuclear translocation allowing the phosphorylation and activation of transcription factors, including the ETS family, to regulate gene expression and modulate many critical aspects of cell physiology. For example, ERK1/2 signalling drives the expression of many transcription factors (e.g., FOS, FRA1, EGR1) which in turn control the expression of genes involved in feedback regulation of the pathway (see below), control of cell cycle progression (CCND1, p21CIP1, p16INK4A) and control of cell survival (MCL1, BCL2, BCL-X L ). ERK1/2 also target a large number of cytoplasmic substrates enabling the pathway to regulate further processes including cell migration and apoptosis (not shown). The ERK1/2 pathway is regulated by an extensive range of negative feedback systems, allowing the fine-tuning of magnitude, duration and localisation of pathway output. These negative feedback controls can be divided into two major mechanisms. The first is the rapid ERK1/2-catalysed inhibitory phosphorylation of upstream pathway components such as BRAF, CRAF, MEK1, SOS and some receptor tyrosine kinases (RTKs) (shown in red). The second mechanism requires the de novo expression of negative regulators including MAP Kinase Phosphatases (MKPs or DUSPs) and Sprouty proteins (shown in green). This delayed, long term mechanism acts to dampen pathway activity following induction of the required pathway output. The ERK1/2 pathway is frequently de-regulated in cancer due to mutations in components such as BRAF, RAS, NF1, MEK or certain RTKs (indicated by yellow stars). Bridges, and Saltiel, 1995) . Other MEK inhibitors quickly followed (Caunt et al., 2015) and the availability of these probes quickly led to the recognition that ERK1/2 signalling was a major pathway by which growth factors and RAS drive cell proliferation (Meloche and Pouysségur, 2007) .
Despite these early studies there was some delay before mutant forms of RAF, MEK or ERK proteins were identified in human cancer. Prior to this a variety of studies demonstrated that engineered mutant forms of RAF or MEK proteins that were constitutively active could confer malignant transformation upon tissue culture cells whereas inactive dominant interfering forms of RAF, MEK or ERK could inhibit RASdependent transformation. The subsequent demonstration of activating mutations in BRAF (notably BRAF V600E ) in human cancer (Davies et al., 2002) , especially in melanoma but also thyroid, colorectal and more recently hairy cell leukaemia (Tiacci et al., 2011) , was a landmark and provided critical validation that core components of the ERK1/2 pathway were subject to disease-driving mutations in human cancer. More recently, activating oncogenic mutations in MEK1 or MEK2 have been described in melanoma, colorectal cancer and lung cancer (Caunt et al., 2015) . Although the incidence of activating mutations in MEK1 or MEK2 is much lower than that of RAS or BRAF they may define a subset of lung adenocarcinoma (Arcila et al., 2015) and provide a critical validation that the RAF-MEK-ERK1/2 pathway is a common cancerdriving pathway. In addition, emergent mutations in MEK1 or MEK2 are also seen in tumours that have acquired resistance to BRAF or MEK inhibitors (see below).
Mutations in ERK1 or ERK2 have been reported on the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). In addition, the ERK2 E322K mutant has been observed at significant frequency in cervical and head and neck squamous cell carcinomas (Arvind et al., 2005; Lawrence et al., 2014; Ojesina et al., 2014) . This mutant maps to the D-recruitment site or common docking domain and may exhibit more sustained activity due to defects in DUSP binding. However, it is apparent that primary disease driving mutations in ERK1 or ERK2 tend to be rarer than BRAF or even MEK1/2 mutations. Despite this, ERK1/2 remain very well validated targets themselves for a variety of critical reasons. First, the pathway topology suggests that signalling proceeds in a linear fashion, namely RAF-N MEK1/2-N ERK1/2, and the overwhelming body of evidence supports this contention. ERK1 and ERK2 exhibit N80% sequence identity (Boulton et al., 1991; Buscà et al., 2016) and are the only known substrates for the dual threonine/ tyrosine kinase activity of MEK1/2. For example, despite the kinase domain ERK5 being highly related to ERK1 and ERK2 (66% sequence identity) and including the same T-E-Y motif within its activation loop, MEK1 fails to bind to ERK5 (Zhou, Bao, and Dixon, 1995) and fails to activate ERK5 in cells (Gilley, March, and Cook, 2009) . Indeed, N20 years on from their discovery there is no convincing evidence that MEK1 or MEK2 serve any function other than to activate ERK1/2, a contention supported by the similar early embryonic lethality and placental disruption observed in Mek1−/− mice (Giroux et al., 1999) and Erk2−/− mice (Saba-El-Leil et al., 2003) . Much the same can be argued for the RAF proteins. Wild type RAF proteins act as RAS-dependent homo-or heterodimers (Freeman, Ritt, and Morrison, 2013) and can activate their dimer partners in trans whilst the common BRAF V600E mutant is constitutively active and acts as a monomer; however, in both cases the only known and universally accepted catalytic function of activated RAF proteins is to phosphorylate and activate MEK1 and MEK2. The significance of interactions between RAF proteins and components of other signalling pathways such as MST2 (Nguyen, Matallanas, Romano, Kholodenko, and Kolch, 2015) or ASK1 (Chen, Fujii, Zhang, Roberts, and Fu, 2001) in cancer is at present unclear. Below ERK1/2, signalling diverges to hundreds of ERK1/2 substrates and interacting proteins (Carlson et al., 2011; Courcelles et al., 2013; von Kriegsheim et al., 2009; Kubiniok, Lavoie, Therrien, and Thibault, 2017 ) that each mediate a subset of the global effects of ERK1/2 signalling. Whilst some of these ERK1/2 substrates are kinases themselves, and therefore druggable, the effect of targeting these components is limited to a subset of ERK1/2-dependent events and processes and this inevitably limits efficacy. Indeed, ERK1/2 can be viewed as playing a pivotal distributive role in the pathway, receiving information from MEK1/2 and then passing it on to hundreds of targets. Thus, the core RAF-MEK1/2-ERK1/2 pathway can be viewed as a critical bottleneck with inhibition of ERK1/2 signalling achievable by targeting at the level of RAFs, MEK1/2 or ERK1/2. Second, innate resistance to clinically approved RAFi or MEKi arises through relief of negative feedback and ERK1/2 pathway re-activation, validating the use of ERKi with RAFi or MEKi as an upfront combination (see Section 4 below). Third, long-term acquired resistance to RAFi or MEKi arises through a variety of mechanisms but the majority of these re-instate ERK1/2 activity validating the use of ERKi to forestall or overcome acquired resistance to RAFi or MEKi (Caunt et al., 2015; Little, Smith, and Cook, 2013 ) (see below).
Experiences of RAF and MEK1/2 inhibitors
The first ERK1/2 pathway inhibitor to be clinically approved was the RAFi sorafenib, which is now used in the treatment of renal cell carcinoma, liver and thyroid cancer, though its efficacy is thought reflect its significant activity against several RTKs (Wilhelm et al., 2004) . The real breakthrough in ERK1/2 pathway therapeutics came with the description of the BRAF inhibitor (BRAFi) vemurafenib, which emerged from a structure-based drug design process and exhibits selectivity for the mutationally activated forms of BRAF, especially the commonest BRAF V600E mutant, that is particularly abundant in melanoma (Joseph et al., 2010) . Indeed, BRAF V600E -positive melanoma cells are acutely addicted to their driving oncoprotein and ERK1/2 signalling, such that BRAFis like vemurafenib cause striking inhibition of melanoma cell proliferation and tumour regression in the clinic . This led to the rapid clinical approval of vemurafenib, and subsequently dabrafenib, both of which have transformed the treatment of melanoma driven by BRAF V600 mutants (Holderfield et al., 2014) . The high incidence of BRAF V600E mutations in hairy cell leukaemia suggests that
BRAFis may hold promise in this disease also (Tiacci et al., 2015) . However, the striking efficacy of BRAFis is very much limited to BRAF V600 -mutant tumours where the mutant oncoprotein signals as a monomer. In cells with wild type BRAF, which signals as dimer, binding of BRAFi to one protomer elicits conformational changes in the dimer partner that result in its activation, driving MEK1/2 and ERK1/2 activation (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Holderfield et al., 2013; Poulikakos, Zhang, Bollag, Shokat, and Rosen, 2010) . This paradoxical RAF activation requires RAS-dependent RAF dimerization and so is especially profound in cells with activating mutations in RAS, upstream components (RTKs) or negative regulators of RAS (NF1). A consequence of this paradoxical RAF activation is the development of a range of secondary cutaneous lesions, including papillomas, squamous cell carcinomas and basal cell carcinomas, all of which limit the efficacy of BRAFi monotherapy to those cells harbouring BRAF V600 mutants (Holderfield et al., 2014) . The very strong ERK1/2 pathway addiction observed in BRAF V600E melanoma has meant that MEKis are also effective, with the result that the MEKis trametinib and cobimetinib are both approved for the treatment of this disease (Caunt et al., 2015) . However, because MEKis are not selective for mutant forms of MEK1/2 (as is the case for vemurafenib and BRAF
V600E
) and MEK1 and MEK2 are more rarely mutated in cancer there is a less profound therapeutic index; as a result the efficacy of MEKi monotherapy is currently limited by toxicity in normal tissue. This toxicity is mitigated by combination with BRAFi. Indeed, the recognition that acquired resistance to BRAFi most frequently involves re-activation of MEK1/2-ERK1/2 signalling quickly led to the development of BRAFi+MEKi combination therapies (Long et al., 2014) and cobimetinib is actually approved as part of a BRAFi combination. At least three different BRAFi+MEKi combinations have been tested and in all cases provide improved response rates and improved progression free survival and overall survival with fewer side effects (Queirolo, Picasso, and Spagnolo, 2015) . This increased therapeutic index reflects two unique aspects of the drug combination. First, the drugs synergise to cause a more profound and durable inhibition of ERK1/2 signalling in BRAF V600E tumour cells. Second, they are thought to antagonise each other in normal cells with wild type BRAF; this is because the MEKi counters the paradoxical activation of ERK1/2 by BRAFi, whilst the paradoxical effects of BRAFi counter ERK1/2 inhibition by MEKi (Caunt et al., 2015; Holderfield et al., 2014) . As a result, the combination has now become the standard of care in patients with BRAF V600 -mutated advanced melanoma (Holderfield et al., 2014) .
That said, the experience with BRAFi or MEKi monotherapy and with BRAFi+MEKi combination therapy is that BRAF V600 -mutated tumours will eventually adapt and acquire resistance (Ahronian et al., 2015) . In the vast majority of cases resistance involves reactivation of the ERK1/2 pathway through a variety of different mechanisms (Ahronian et al., 2015; Little et al., 2013) . These include: amplification of genes encoding mutant RAS proteins or BRAF V600E (Corcoran et al., 2010; Little et al., 2011) ; the emergence of BRAF splice variants (Poulikakos et al., 2011) ; a switch to other RAF isoforms (Villanueva et al., 2010) or other MEK activators (Johannessen et al., 2010) ; or the emergence of MEK1/2 mutations (Ahronian et al., 2015; Little et al., 2013) . In these cases there is a strong rationale for inhibiting at the level of ERK1/2 to forestall or overcome acquired resistance. RAFis are not appropriate for use as monotherapy in tumours with wild type RAF that are driven by mutations in RAS or components upstream of RAS since they promote RAS-dependent paradoxical activation of RAF and so fail to inhibit, and may even promote ERK1/2 signalling. This is not an issue with MEKi and inhibition of MEK1/2 remains an attractive option in RAS-mutant or RAS-dependent tumours (Caunt et al., 2015) . Most clinical trials with MEKi monotherapy in solid tumours have reported clear but modest response rates. A notable exception is the durable response rate to the MEKi selumetinib in paediatric neurofibromatosis type 1 (NF1), a disease associated with loss of RAS-GAP activity and increased activation of wild type RAS (Dombi et al., 2016) . However, it is increasingly apparent that MEKis may require combination with other agents to fulfil their potential (Caunt et al., 2015) and one important combination option is dual intrapathway inhibition through combination with a RAFi or ERKi. One major limitation of MEKi monotherapy, especially in tumours with mutant RAS, is the rapid rebound in pathway activation. The ERK1/2-dependent feedback loops that inhibit MEK1 and the RAF proteins are lost when cells are treated with MEKi with the result that RAF is reactivated. Since cells typically only utilise a small fraction of their total MEK1/2 and ERK1/2 this means there is considerable spare MEK1/2 that can be activated following loss of feedback and which will reinstate or sustain ERK1/2 signalling. This pathway reactivation following loss of feedback (or feedback relief) is much reduced in cells with BRAF V600E (Friday et al., 2008; Pratilas et al., 2009) , which signals as a monomer and although still subject to ERK1/2-dependent phosphorylation (Ritt et al., 2010) appears to be refractory to the inhibitory effects of this ERK1/2-dependent phosphorylation. However, ERK1/2 rebound is particularly robust in cells with mutant RAS and therefore limits the durability of pathway inhibition and clinical response. In summary, the lessons learnt from BRAFi and MEKi are that durable ERK1/2 pathway shutdown can be achieved in the case of BRAF V600 -mutant melanoma and this can translate into striking clinical responses. However, these responses are usually short-lived (6-9 months) due to the emergence of acquired resistance which typically involves reinstating MEK1/2-ERK1/2 signalling. In cells with wild type BRAF, including those with RAS mutation, MEKi elicits only transient pathway inhibition that quickly (hours or a few days) rebounds, limiting primary efficacy. In both cases dual pathway inhibition is indicated, validating ERKi as a rational combination with BRAFi or MEKi.
Small molecule inhibitors of ERK1/2 activity
Protein kinase catalytic domains share a common structure characterised by the amino-and carboxy-terminal kinase lobes connected by a hinge region (Zhang, Yang, and Gray, 2009 ). The ATP binding pocket is located in a cleft between the two lobes adjacent to the hinge region, forming a highly druggable cavity which has been the focus of most kinase inhibitor development (Müller, Chaikuad, Gray, and Knapp, 2015) . However, kinase inhibitors can vary based on the activation status of the kinase that is preferentially recognised (active or inactive), the mechanism of binding (reversible or covalent) and the binding site (ATP-binding pocket or allosteric) (Gross, Rahal, Stransky, Lengauer, and Hoeflich, 2015) . Therefore, kinase inhibitors have been categorised based on their binding mode.
All kinases have a conserved Asp-Phe-Gly (DFG) motif at the N terminus of the activation loop, which is important for regulating kinase activity. When a kinase is active the DFG phenylalanine sits in the hydrophobic pocket between the N-and C-lobes of the kinase, bringing the DFG aspartate into position to coordinate magnesium at the active site. Kinase inactivation can occur if the phenylalanine moves out of the hydrophobic pocket, disrupting the orientation of the aspartate and in some cases sterically blocking ATP binding . Type I kinase inhibitors are ATP-competitive compounds that target the ATP-binding pocket when the activation loop is in an active, "DFG-in", conformation and mimic the hydrogen bonding normally formed by the adenine ring of ATP. In contrast, type II kinase inhibitors recognise, or induce the formation of, an inactive, "DFG-out" conformation of the active site, thus trapping the kinase in its inactive conformation. Furthermore, this "DFG-out" conformation exposes an extended, diverse binding pocket consisting of an additional hydrophobic region directly adjacent to the ATP binding site ). Due to this increased structural diversity it has been postulated that type II inhibitors may have improved selectivity within the kinome, although the evidence for this is less clear (Zhao et al., 2014) .
Instead of targeting the highly-conserved ATP-binding pocket, kinase inhibitors can be targeted to other less-conserved allosteric pockets on the target kinase. Allosteric kinase inhibitors can be classified as either type III inhibitors, which bind in a pocket adjacent to the ATPbinding site in a mechanism that does not compete with ATP binding, but may displace it, or type IV inhibitors, which bind to an allosteric site distinct from the substrate/ATP-binding sites (Wu, Clausen, and Nielsen, 2015) . Other classes of kinase inhibitors include bivalent type V inhibitors that combine elements from types I-IV inhibitors (Lamba and Ghosh, 2012) , and covalent inhibitors which are able to form irreversible covalent bonds to the kinase active site, typically by reacting with a nucleophilic cysteine residue (Bauer, 2015) .
Within the last 15 years, many small molecule inhibitors of ERK1/2 activity have been described in the literature and some of these have progressed into clinical trials (Table 1) . Based on their mechanism of action, these ERKis can be classified into four distinct groups, which might have significant consequences for how cells respond and adapt. The majority of the ERKis in development target ERK1/2's catalytic activity in a reversible, ATP-competitive manner. These reversible catalytic ERKis can be further stratified based on their ability to interfere with the activating phosphorylation of ERK1/2 at its pT-E-pY motif by MEK1/2. Catalytic ERKis solely possess the ability to inhibit ERK1/2 catalytic activity (that is phosphorylation of ERK1/2 substrates), whereas "dual mechanism" ERKis are characterised by their ability to antagonise T-E-Y phosphorylation and thus prevent the formation of the active conformation of ERK1/2, in addition to inhibiting ERK1/2 catalytic activity. Additionally, some covalent ERKis are in development; these inhibitors also target the ERK1/2 active site but are characterised by a prolonged duration of activity due to the formation of an irreversible covalent bond to the target site. Finally, a range of approaches have been published attempting to generate allosteric ERKis, which selectively modulate the ability of ERK1/2 to interact with its binding partners, The year reported is based on the earliest publication or clinical trial start date of the compound in question. a No evidence these compounds are able to inhibit the phosphorylation of ERK and therefore possess a "dual mechanism", however limited in vivo biological data has been published for these compounds. b Due to their nature as covalent inhibitors, IC 50 values cannot be compared between assays, as the time of incubation will affect the relative potency of the compounds. c Structure of LY3214996 is taken from Selleck Chem, which corresponds to a structure disclosed within an Eli Lily patent, however, to our knowledge the structure has not been disclosed in any primary literature.
and thus enabling more precise regulation of ERK1/2 activity or ERK1/2 biological effects.
Reversible, ATP-competitive ERK1/2 inhibitors
In 2005 Astellas Pharmaceuticals published the first report of a small molecule ERKi. FR180204 (1 -Table 1) was identified from an in-house chemical library utilising a high-throughput kinase screen to identify compounds capable of inhibiting ERK1/2-catalysed phosphorylation of myelin basic protein (MBP) (Ohori et al., 2005) . FR180204 inhibited the in vitro kinase activity of ERK1 and ERK2 with IC 50 values of 0.51 μM and 0.33 μM respectively, and was shown to be very selective against ERK1/2 over a group of other kinases including MEK1, with the exception of the structurally-related MAPK p38α (IC 50 10 μM). The co-crystal structure of FR180204 bound to ERK2 revealed that the compound targeted the ATP-binding pocket and this evidence, together with Lineweaver-Burk analysis of the binding interaction, demonstrated that FR180204 acted as an ATP-competitive inhibitor of ERK1/2.
The first nanomolar potency inhibitors of ERK1/2 were a pyrrolebased series from Vertex Pharmaceuticals which were developed through structure-guided optimisation (Aronov et al., 2007) . This work led to the publication of VTX-11e (5 - (Germann et al., 2015; Li et al., 2017) .
Following the development of VTX-11e/BVD-523 a range of other reversible, ATP-competitive ERKi have been published including SCH772984 (6 -Merck) (Morris et al., 2013) , an unnamed tetrahydropyrrolo-diazepenones series (10 -Novartis) (Bagdanoff, Jain, Han, Poon, et al., 2015; Bagdanoff, Jain, Han, Zhu, et al., 2015) , GDC-0994 (7 -Genentech) (Blake et al., 2016) and an unnamed pyrrolopyrazinone-based series (16 -AstraZeneca) (Ward et al., 2017) . In addition to BVD-523, GDC-0994 and MK-8353/SCH900353 (a derivative of SCH772984 selected for clinical development), undisclosed compounds from Eli Lily (LY3214996) and Novartis (LTT462) have reached phase I clinical trials.
Of these compounds perhaps the most unique is SCH772984, as this compound was shown to effectively inhibit both ERK1/2 catalytic activity as well as its phosphorylation by MEK1/2 on its activating pT-E-pY motif (Morris et al., 2013) . This dual mechanism of action demonstrated by SCH772984 clearly contrasted with that of the previously disclosed ERKi VTX-11e, which in cell-based assays was only able to inhibit ERK1/2 catalytic activity (measured by the phosphorylation of the ERK1/2 substrate p90RSK), and not the phosphorylation of ERK1/2 itself. Interestingly, when the effects of SCH772984 treatment were examined over a 36-hour time-course in A375 cells the pathway rebound, following feedback relief, was able to overcome the inhibition of ERK1/2 phosphorylation, but not the inhibition of p90RSK phosphorylation, which was maintained. This indicates that SCH772984 is more effective at inhibiting ERK1/2 catalytic activity than the phosphorylation of ERK1/2 by MEK1/2 (Morris et al., 2013) .
SCH772984 is structurally distinct from ERKis 5, 8, 10 and 7, all of which feature N-acyl β-amino alcohols, being formed of a hinge binding pyridine-indazole with an extended piperazinephenyl-pyrimidine decoration ( Fig. 2A) . Furthermore, the dual mechanism of action of SCH772984 suggested that it was able to either bind inactive ERK1/2 to prevent the phosphorylation and activation of the kinase, or facilitate dephosphorylation of the active kinase. This mechanism of action and its unique structure led to the initial theory that SCH772984 displayed properties of both type I and type II kinase inhibitors (Chaikuad et al., 2014; Morris et al., 2013) . If so this would contrast with other previously reported reversible, ATP-competitive ERK inhibitors; for example, cocrystal structures have indicated that VTX-11e exclusively exhibits a type I binding mode (Fig. 2B) (Aronov et al., 2009; Chaikuad et al., 2014; Ohori et al., 2005) . The prevalence of type I inhibitors, also seen within the GDC-0994 crystal structure (Fig. 2C) , is thought to be due to residues in the catalytic domain of ERK1/2 stabilising the "DFG-in" conformation (Hari, Merritt, and Maly, 2013) , thereby minimising the availability of a "DFG-out" state for type II kinase inhibitor development. However, detailed structural analysis of SCH772984 bound ERK1 or ERK2 subsequently revealed that the inhibitor did not extend into the type-II binding pocket; rather the compound induced a novel binding pocket located between the phosphate binding loop (P-loop) and αC helix making a π-stacking interaction with Y64 ( Fig. 2A) (Chaikuad et al., 2014) . This binding pocket was not present in unphosphorylated, inactive or phosphorylated, active forms of the kinase. To generate this binding pocket SCH772984 induces significant structural distortion of the P-loop, where Y36 is flipped into the ATP pocket above the pyrrolidine ring of SCH772984. This distortion creates the binding pocket between the P-loop and helix αC, occupied by the pyrimidine ring of SCH772984, whilst not affecting other key elements, leaving the DFG motif in an "in" conformation (Chaikuad et al., 2014) . Multiple kinases can form folded P-loop conformations and this binding mode correlates with a high degree of selectivity (Müller et al., 2015) .
During the development of SCH772984, researchers at Merck identified initial hit compounds that were able to bind to both unphosphorylated, inactive and phosphorylated, active ERK2. Therefore, as well as a conventional, active ERK2 enzyme assay, they developed a coupled ERK2 assay where unphosphorylated ERK2 was pre-incubated with the test compound, then the ability of ERK2 to phosphorylate a polypeptide substrate was measured following the addition of active MEK1. This coupled assay encompasses the processes of phosphorylation and activation of ERK2 (and attendant conformational changes) and its ability to phosphorylate a substrate; it can therefore capture the inhibition of both inactive and activated ERK2 (Deng et al., 2014; Zhu et al., 2015) . SCH772984 demonstrated high ERK1/2 potency, kinome selectivity and in vivo efficacy but its high molecular weight and poor ligand efficiency (LE) could present problems later in development, therefore more drug-like properties were sought through a novel series. Interestingly, when developing a further compound series with lower molecular weight and higher LE, researchers at Merck selected a lead compound which apparently did not retain the ability to inhibit the phosphorylation of ERK1/2 (Lim et al., 2016) . To what extent this choice suggested that the dual mechanism of action, and specifically the inhibition of T-E-Y phosphorylation, was not sufficiently valued is unclear. It will be interesting to see what mechanism of action is ultimately selected as this programme develops.
Recently, when developing a novel pyrrolopyrazinone-based series of reversible, ATP-competitive ERKi researchers at AstraZeneca also determined the ability of their compounds to prevent the activation of ERK1/2, in this case by measuring the levels of phosphorylated ERK1/2 following 2 h treatment of A375 melanoma cells (Ward et al., 2017) . This study revealed that relatively minor changes in the structure of the compound, such as switching the chirality of a single methyl group, could have significant impacts on the ability to inhibit ERK1/2 phosphorylation, yet retain a similar ability to inhibit ERK1/2 catalytic activity. This indicates that dual-mechanism and catalytic ERKis are unlikely to be distinct classes, but rather two extremes of a spectrum of compounds with the ability to prevent ERK1/2 phosphorylation. Structure-activity relationships indicated that the interactions between the compound and the glycine-rich loop of ERK1/2 might influence the ability of the compound to inhibit ERK1/2 phosphorylation. However, further studies are required to identify the key requirements for this binding mode, and the mechanism by which it prevents ERK1/2 phosphorylation. The lead compound from this study, compound 35 (16), is a potent, selective ERKi with an in vitro IC 50 of b0.3 nM, IC 50 's of 12/ 62 nM for inhibition of p-ERK1/2 and p-p90RSK respectively in A375 cells and efficacy in tumour xenograft models (Ward et al., 2017) . This data suggests that compound 35 possesses a dual mechanism, however the co-crystal structures generated for this compound series appear to show a binding mode more similar to that of the catalytic ERKi VTX11e than the dual mechanism inhibitor SCH772984. Therefore, it would be interesting to determine whether this compound is able to induce robust, durable inhibition of p-ERK in RAS mutant cell lines that are more liable to feedback relief and pathway rebound.
To generate a dual mechanism profile compounds are likely to induce or stabilize a conformational state in ERK1/2 that prevents the binding of, or activation by, MEK, in addition to the ATP-competitive inhibition of ERK1/2 catalytic activity. However, with the exceptions of VTX-11e, SCH772984 and Compound 35 very little biological data has been published for most reversible, ATP-competitive ERKis, therefore it is not possible to determine how many of these inhibitors are solely catalytic, or possess a dual mechanism of action. However, based on the precedent of MEKis, we speculate that these two mechanisms of action (dual mechanism versus purely catalytic) could have significant consequences for how cells respond and adapt following compound treatment. In the context of MEKi, compounds that are able to block the phosphorylation of MEK1/2 by RAF, in addition to inhibiting the catalytic activity of MEK1/2, have been shown to delay pathway rebound following the collapse of negative feedback (Hatzivassiliou et al., 2013; Ishii et al., 2013) . These MEKi, which include trametinib, CH5126766 and GDC-0623, have been termed "feedback buster MEKis" due to their ability to mitigate some of the consequences of feedback relief and induce a more durable inhibition of ERK1/2 phosphorylation and cell proliferation in RAS mutant cell lines (Caunt et al., 2015; Hatzivassiliou et al., 2013; Lito et al., 2014) . Consequently, it is possible to hypothesise that ERKis would also follow this paradigm with dual mechanism ERKis delaying pathway rebound relative to solely catalytic inhibitors due to their ability to prevent the phosphorylation and activation of ERK1/2 by MEK1/2. This is to some extent supported by the durable inhibition of p90RSK phosphorylation observed in the context of negative feedback relief and pathway rebound following SCH772984 treatment of A375 melanoma cells (Morris et al., 2013) . However, this conclusion is clouded by the fact that A375 cells harbour BRAF V600E , which is known to exhibit weaker pathway rebound due to feedback relief following ERK1/2 pathway inhibition, as BRAF V600E is active as a monomer and insensitive to ERK1/2 inhibitory phosphorylation (Pratilas et al., 2009) . Furthermore, no studies to date have compared the ability of catalytic and dual mechanism ERKi to maintain durable inhibition of ERK1/2 activity, therefore it is possible that targeting ERK1/2 will result in prolonged pathway inhibition no matter which mechanism of inhibitor is used. Catalytic ERKi treatment has been shown to result in the accumulation of p-ERK (Goetz, Ghandi, Treacy, Wagle, and Garraway, 2014; Morris et al., 2013) , and the phosphorylation of ERK1/2 is known to induce its release from its cytoplasmic anchor MEK1/2 and enable its subsequent translocation to the nucleus (Plotnikov, Zehorai, Procaccia, and Seger, 2011) . Together this evidence indicates that catalytic ERKi treatment might induce the nuclear accumulation of phosphorylated, but inhibited ERK1/2, whereas dual-mechanism ERKi would prevent the nuclear translocation of inhibitor bound ERK1/2 (Fig. 3) . This "primedstate" following catalytic ERKi treatment may facilitate accelerated nuclear ERK1/2 activity and ERK1/2-dependent gene expression when pathway rebound overcomes compound efficacy, and could potentially result in cells recovering more rapidly from treatment with catalytic ERKi compared to dual-mechanism ERKi.
Alternatively, this nuclear p-ERK1/2 pool induced by catalytic ERKi treatment could potentially play a role in maintaining the noncatalytic functions of ERK1/2. Although it is clear that the vast majority of the biological functions of ERK1/2 are performed via phosphorylation events, evidence for non-catalytic functions of ERK1/2 is accumulating. Direct interaction with ERK2 has been shown to activate a range of Fig. 2 . Crystal structures of a number of ERK1/2 inhibitors bound to ERK2. (A) SCH772984 binds to the hinge region of the kinase, with the kinase adopting a "DFG-in" conformation. SCH772984 also binds within a new pocket between the αC helix and the P-loop of the kinase, revealed when Y36 flips into the ATP pocket, within which the terminal pyrimidine of SCH772984 makes a π-stacking interaction with Y64. (B-C) VTX-11e and GDC-0994 both bind to ERK2 in a manner consistent with Type I inhibitors, with the kinase in a "DFG-in" conformation and with Y36 outside of the ATP pocket. (D) Compound 10 binds to the hinge region of ERK2, presenting the electrophilic acrylamide towards C166, which subsequently reacts to form a covalent bond, as shown in crystal structure. Main structure of the protein is shown as a ribbon in orange with certain areas highlighted for clarity, hinge -dark blue, P-loop -dark green, αC helix -violet, DFG motif -red, Y64 -purple, Y36 -light blue. Inhibitors are shown with carbon -light green, nitrogen -blue, oxygen -red, chlorine -dark green, fluorine -cyan, sulphur -yellow. Structures were taken from the PDB under the following accession codes; SCH772984 -4QTA, VTX-11e -4QTE, GDC-0994 -5K4I, compound 10 -4ZZO. The PDB structures were modified by removing all solvents and ions for clarity, before colour coding the protein and inhibitors as described above. Images were produced using Maestro 11.1 Schrödinger release 2017-4.
proteins including topoisomerase II (Shapiro et al., 1999) , poly(ADPribose) polymerase (PARP) 1 (Cohen-Armon et al., 2007) and DUSP6 (MAPK phosphatase 3, MKP-3) (Camps et al., 1998) , in a mannerindependent of phosphotransfer activity. ERK2 is also able to act as a transcriptional repressor of interferon-γ responsive genes by directly binding DNA in the promoter regions of these genes and preventing the binding of the transcription factor C/EBP-β (Hu et al., 2009 ). Furthermore, ERK1/2 have been suggested to contribute to regulation of cell-cycle entry in a kinase-independent manner. Upon nuclear translocation ERK1/2 was able to interact with lamin A and displace the retinoblastoma (RB) protein, enabling RB phosphorylation by cyclin-dependent kinases and the release of E2F transcription factors to promote cell cycle entry (Rodríguez et al., 2010) .
Interestingly, with the exception of the activation of its negative feedback regulator DUSP6, the majority of the known non-catalytic functions of ERK1/2 occur in the nucleus. This raises the possibility that these processes are regulated by the nuclear translocation of ERK1/2 for which T-E-Y phosphorylation is a major driver (Lidke et al., 2010) , although not the sole determinant (Caunt and McArdle, 2010) . Therefore, the inability of solely catalytic ERKis to prevent the nuclear accumulation of ERK1/2 could be permitting a range of non-catalytic functions of ERK1/2 to continue. These non-catalytic functions could potentially contribute to reduced efficacy of catalytic ERKis relative to dual mechanism ERKis or RAF/MEK inhibitors which target upstream of ERK1/2 and prevent its phosphorylation and nuclear import.
Overall, current evidence would imply that it could be advantageous to develop dual mechanism inhibitors to target ERK1/2. However, due to the very limited mechanistic data published on the current ATPcompetitive ERKis, the majority of this evidence relies on knowledge gained from studies of ERK1/2 signalling rather than ERK1/2 inhibition or knowledge inferred or extrapolated from the mechanism of action of MEKis. Further studies are required to investigate the different mechanisms of action of current ERKis in the appropriate signalling and disease context to utilise these compounds successfully or to design compounds that are more effective.
Covalent ERK inhibitors
In recent years there has been an increased interest in developing targeted covalent inhibitors for many kinases. This has been driven by the successes of the EGFR/HER2 inhibitors afatinib and neratinib (Li et al., 2008; Park et al., 2016 ) the BTK inhibitor ibrutinib (de Claro et al., 2015) and the EGFR T790M -specific inhibitor osimertinib (Khozin et al., 2017) . Targeted covalent inhibitors act through a two-step mechanism. First, they bind to their target protein through a reversible interaction, which presents an electrophilic moiety within the inhibitor in the correct vector towards a nucleophilic residue within the target protein (typically a cysteine). In the second step this nucleophilic residue then reacts with the inhibitor to form a covalent interaction, which can be either reversible or irreversible depending on the nature of the bond formed (Baillie, 2016; Chaikuad, Koch, Laufer, and Knapp, 2017) . This method of inhibition is proposed to facilitate prolonged inhibition of the target protein and high potency, as the covalent interaction results in either a very slow off-rate for the inhibitor or a permanently inhibited target protein, consequently de novo synthesis of the target is required to re-establish activity. However, a negative consequence of the inherent reactivity of covalent inhibitors is that they may exhibit off-target effects by reacting with cysteines and other reactive residues within the proteome.
An analysis of the kinome, performed by Liu et al., estimated that 200 kinases possess a cysteine either in or proximal to the ATP binding site, including both ERK1 and ERK2 (Liu et al., 2013) . Cys166 of ERK1/2 is a non-catalytic residue located in the back of the ATP binding pocket, one residue prior to the conserved DFG motif. The ability of this cysteine residue to form a covalent adduct with an inhibitor was demonstrated with the resorcyclic acid lactone (RAL) natural product 5Z-7-oxozeaenol (also known as FR148083, 4 -Table 1) (Ohori et al., 2007) . A crystal structure showed it covalently linked to Cys166 of ERK2 through the cis-enone functionality of the RAL to form a covalent adduct. However, 5Z-7-oxozeaenol and structurally related RAL analogues were found to be promiscuous, forming covalent adducts with a number of kinases Fig. 3 . Catalytic and dual mechanism ERK1/2 inhibitors could differentially regulate the localisation of ERK1/2. A purely catalytic ERK1/2 inhibitor should allow the nuclear accumulation of ERK1/2 since it will not prevent activating phosphorylation by MEK1/2. Indeed, in cells with wild type BRAF a catalytic ERK1/2 inhibitor should induce feedback relief, resulting in increased RAF-dependent activation of MEK, leading to further accumulation of p-ERK1/2. The phosphorylation of ERK1/2 promotes its nuclear translocation, therefore a pool of inhibitor-bound ERK1/2 might accumulate in the nucleus. In contrast, dual mechanism ERK1/2 inhibitors could disrupt the phosphorylation of ERK1/2, and reduce the nuclear translocation ERK1/2, resulting in a pool of inhibitor-bound ERK1/2 in the cytoplasm.
that possess a cysteine within their catalytic sites, including MEK1, MKK7, MKK4 and VEGFR1/2 (Ohori et al., 2007; Schirmer, Kennedy, Murli, Reid, and Santi, 2006) .
Building on the discovery that ERK1/2 is susceptible to covalent inhibition, AstraZeneca utilised an approach to develop covalent inhibitors through repurposing of existing scaffolds and a structure-guided screen. This identified a number of compounds that showed good biochemical and cellular activity against ERK2 (Ward et al., 2015) . This compound series binds in the ATP-pocket and forms a covalent bond with Cys-166 (Fig. 2D) . The lead, compound 13 (11 -Table 1) , showed an in vitro IC 50 of 6.9 nM against ERK2 activity and an IC 50 of 53 nM in an A375 cell proliferation assay. However, it should be noted that IC 50 values for covalent inhibitors are dependent on the timing of the assay as longer incubation times will lead to increased proteininhibitor adducts.
This molecular series has since been used as a template for the synthesis of chemical probes to manipulate and study ERK1/2 function. Lebraud et al. appended a trans-cyclooctene (TCO) group to the core pharmacophore of compound 13, allowing for functionalisation of the inhibitor, and as a result its target protein, through biorthogonal chemistry . Such TCO-derivatives have been used for a number of purposes including in-gel activity based protein profiling, whereby the selectivity of the inhibitor can be assessed by reacting the TCO tag with a fluorophore, and identification of protein-inhibitor adducts using an SDS PAGE gel . Further uses of these TCO-derivatives include guiding an E3 ubiquitin ligase to accelerate the degradation of ERK1/2 in a proteolysis targeting chimera (PROTAC) approach (Lebraud, Wright, Johnson, and Heightman, 2016) , and imaging of endogenous inhibitor-bound ERK1/2 using confocal microscopy to track localisation of ERK1/2 within cells (Sipthorp et al., 2017) .
Although covalent inhibitors have the potential to be an effective tool to inhibit ERK1/2 signalling they have yet to achieve any success in the clinic. The only Phase I clinical trial to date utilising a covalent ERKi was initiated by Celgene in 2014, however, this study was terminated because "the maximum tolerated dose (MTD) did not offer a sufficiently encouraging profile to proceed with the additional dosing schedule or the cohort expansion phase" (NCT02313012). This possibly reflects the reactivity of covalent inhibitors and their propensity for offtarget effects. As such further studies are required to develop selective, covalent ERK1/2 inhibitors with efficacy in the clinic.
Allosteric ERK1/2 inhibitors
In addition to targeting the catalytic site of ERK1/2, efforts have been made to develop allosteric ERKis, which bind at sites distinct from the catalytic cleft and interfere with the ability of ERK1/2 to interact with its binding partners. The disruption of protein-protein interactions (PPIs) is considered challenging due to the extensive and sometimes relatively featureless interfaces involved; however the identification of interaction hot-spots led to the appreciation that blocking the entire interface is not required to successfully block PPIs (Whitty and Kumaravel, 2006; Yap, Worlikar, MacKerell, Shapiro, and Fletcher, 2011) . This knowledge, coupled with the diverse structural nature of allosteric binding pockets makes them promising alternatives to catalytic kinase inhibitors, with potentially high selectivity and the ability to target tumours which evolve drug-resistance to conventional catalytic kinase inhibitors (Wu et al., 2015) . Furthermore, ERK1/2 are known to have N200 substrates and/or binding partners and contain two major substrate binding sites, the D-recruitment site (DRS) and the F-recruitment site (FRS); therefore allosteric inhibitors targeted at one site may enable modulation of the activity of select ERK1/2 substrates (Yap et al., 2011) .
Shapiro and colleagues reported the first putative small molecule, allosteric ERKi in 2005 (Hancock et al., 2005) . This study utilised computer-aided drug design to perform an in silico screen for compounds which could target a polar cleft between the acidic common docking (CD) domain and the ED (Glu-Asp) site of the DRS observed in the crystal structure of unphosphorylated ERK2. From this screen, 80 potential compounds were selected for testing in biological assays, of which several were able to inhibit ERK1/2-mediated phosphorylation of the D-domain containing substrates p90RSK and the transcription factor ELK-1. Furthermore, these compounds inhibited the proliferation of several cancer cell lines. Lead compound 76 (2 - Table 1 ) was shown to interact with ERK1/2 in a manner which did not compromise its phosphorylation or catalytic activity, supporting its predicted binding mode to the DRS of ERK1/2 (Hancock et al., 2005) . Structure-activity relationship (SAR) studies have investigated the crucial structural features of compound 76 responsible for its biological activity and further optimised the potency of this compound series (Boston et al., 2011; Jung et al., 2013; Li et al., 2009 ). However, it should be noted that these allosteric inhibitors possess functionality that would not be desirable for a medicinal chemistry program. For example, compound 76 has a core structure of an ene-rhodanine, a reported pan-assay interference compound (PAINS) motif (Baell and Walters, 2014) . Therefore, when using these compounds suitable controls should be put in place to ensure that any effects seen are due to the desired on-target mechanism of action (MOA).
The activation of ERK1/2 by phosphorylation has been suggested to induce subtle structural changes in the region of its DRS (Hoofnagle, Resing, Goldsmith, and Ahn, 2001) , therefore Shapiro and colleagues performed a second in silico screen to identify compounds which potentially bind the DRS of phosphorylated ERK2 (Chen et al., 2006) . The majority of compounds identified by this second screen were the same as those identified by the initial screen. However, the screen also revealed a group of novel compounds (3 -Table 1), which were able to bind ERK1/2 and inhibit the phosphorylation of p90RSK and ELK-1 (Chen et al., 2006) . Finally, Shapiro and colleagues have also applied this in silico screening approach to identify compounds which potentially bind to the FRS of unphosphorylated ERK2 (Samadani et al., 2015) . The FRS is thought to be responsible for the interaction of ERK1/2 with a distinct set of substrates compared to the DRS, although some substrates such as ELK-1 have been shown to utilise both domains to bind to ERK1/2 (Burkhard, Chen, and Shapiro, 2011) . The ERK2-FRS in silico screen identified a diverse range of compounds which inhibited EGFstimulated phosphorylation of ELK-1, but not p90RSK, in HeLa cells, supporting a MOA which inhibits FRS-mediated ERK2 interactions. The binding of these compounds was modelled in silico, enabling the utilisation of structural information and site identification by ligand competitive saturation (SILCS) simulations to optimise the compound series. The resulting lead compound, SF-3-030 (12 -Table 1) , was shown to inhibit ELK-1 phosphorylation, the expression of ERK1/2-dependent immediate early genes and proliferation in BRAF-mutant melanoma cell lines (Samadani et al., 2015) . However, SF-3-030 also contains moieties that may be widely reactive to protein residues, such as its vinyl sulfone, which could undergo undesired covalent linkages to proteins. Again, suitable controls will need to be in place to ensure that the phenotype observed is due to prevention of ERK1/2 FRS-mediated interactions and inhibition of downstream signalling. For example, these agents should be ineffective in cells that are not addicted to ERK1/2 signalling.
In addition to the DRS and FRS, the mutagenesis of ERK2 has identified a range of other residues that could be important for its interactions with substrate or regulatory proteins (Zhang, Zhou, Zheng, and Zhang, 2003) . These include a unique region within the MAP kinase insert which appears to specifically regulate interactions with MEK1/2 (Robinson, Whitehurst, Raman, and Cobb, 2002 ) and a leucine-rich dimerisation interface (Khokhlatchev et al., 1998; Wilsbacher et al., 2006) . Therefore, if further ERK1/2 binding domains are characterised, this could facilitate the development of additional allosteric ERK1/2 inhibitors. ERK1/2 activation by phosphorylation is known to induce dimerisation, as well as substrate binding (Khokhlatchev et al., 1998) . Recent molecular biology studies have shown that ERK1/2 dimers and scaffolds are required for the optimal activation of cytoplasmic, but not nuclear, substrates and that preventing ERK1/2 dimerisation is able to inhibit tumour cell proliferation and tumour development (Casar, Pinto, and Crespo, 2008) . This evidence validated ERK1/2 dimerisation as a potential target for the development of novel ERK inhibitors, therefore Herrero and colleagues developed a native gel electrophoresis approach to screen for inhibitors of ERK1/2 dimerisation (Herrero et al., 2015) . This screen identified DEL-22379 (13 -Table 1) as a small molecule capable of inhibiting ERK1/2 dimerisation, without affecting ERK1/2 phosphorylation or catalytic activity. DEL-22379 inhibited the phosphorylation of ERK1/2 cytoplasmic substrates and the proliferation of tumour cell lines and xenografts harbouring RAS-ERK1/2 pathway oncogenes. Furthermore, DEL-22379 demonstrated efficacy against BRAF or MEK inhibitor resistant cells, and hypothetically could potentially retain efficacy in cases where cell lines evolve resistance to ATP-competitive ERK1/2 kinase inhibitors (Herrero et al., 2015) .
Together these academic studies have revealed that it is possible to inhibit different ERK1/2 binding interactions, advocating the continued development of allosteric approaches to inhibit ERK1/2. Such efforts have identified a range of compounds that inhibit different ERK1/2-substrate interactions, which could be of use for biochemical studies of ERK1/2 function, as well as having the potential to be developed into therapeutic agents. However, many of the molecules identified to date possess moieties that have been reported as PAINS, such as electrophilic Michael acceptors that predispose them to non-specific protein interactions. Consequently, these compounds may induce many offtarget effects, complicating their use as tool compounds without proper controls in place.
Prospects for ERK1/2 inhibitors as monotherapy and in combination
Work described in the previous sections clearly validates the use of ERKis as a new weapon to treat tumours that are driven by mutational activation of the ERK1/2 pathway. Since mutations in ERK1/2 are quite rare in human cancer and, as far as is known, ERKis do not discriminate between mutationally activated or wild type ERK1/2 it must be anticipated that ERKi monotherapy will face the same challenges as MEKi monotherapy; the most obvious being a narrow therapeutic index arising from the inhibition of ERK1/2 signalling in both normal and tumour cells and resultant toxicity. Indeed, reports from the Phase I dose escalation and expansion study of BVD-523/ulixertinib reported similar adverse events as those previously seen with MEKi including rash, diarrhoea, fatigue and nausea (Li et al., 2017) . However, this trial also revealed some encouraging results; the 9 patients (of 83) who exhibited a partial response were found to have tumours with mutations in BRAF (V600E, G469A or L485W) or NRAS, suggesting that clinical activity was related to pathway de-regulation and ERK1/2 addiction. Indeed, the most obvious use for ERKi monotherapy is in the treatment of patients with BRAF-mutant cancer that has initially responded well to BRAFi (and is therefore addicted to ERK1/2 signalling), but has then developed resistance through "on-pathway" mechanisms that reinstate ERK1/2 signalling.
Beyond monotherapy there is clearly a strong case for developing ERKi combinations with other ERK1/2 pathway inhibitors. As with MEKis, ERKis would be expected to antagonise the activation of ERK1/ 2 observed in normal cells arising from paradoxical RAF activation. Thus, BRAFi+ERKi combinations would be expected to have superior efficacy and be better tolerated than BRAFi alone in BRAF V600 melanoma as is the case for BRAFi+MEKi. As outlined above, there is also a strong case for testing ERKi in combination with either RAFi or MEKi to mitigate ERK1/2 reactivation arising from feedback relief in tumour cells with RAS mutations. Beyond the ERK1/2 pathway, ERKi should certainly be tested with other emerging targeted agents (inhibitors of MTOR, PI3K or PKB/Akt) as well as with appropriate "standard-of-care" cytotoxic chemotherapy in tumours with RAS mutations. A further attractive option will be to combine ERKi with inhibitors of cell survival pathways.
In common with MEKi, ERKi typically exert a cytostatic effect and this is most likely due to the buffering effect of pro-survival BCL2 proteins (BCL2, BCL-X L , MCL1) (Cook et al., 2017) . A series of "BH3 mimetics" that bind and inhibit the activity of select pro-survival proteins have already been developed and are undergoing clinical evaluation and there is already precedent that RAFi or MEKi can synergise with these agents to promote cell death in ERK-addicted tumour cells (Corcoran et al., 2013; Cragg et al., 2008; Sale and Cook, 2013) . Finally, ERKi (with MEKi or BRAFi) will undoubtedly be tested in combination with immunotherapy; indeed pre-clinical models have supported the testing of BRAFi+MEKi+immunotherapy in BRAF V600E melanoma models (Hu-Lieskovan et al., 2015) . The challenge with all these combinations will be to balance any synergy in the tumour cell with the increased toxicity arising from activity in non-tumour tissue. Dosing, scheduling and stratification biomarkers for identifying responsive patient populations will all play a part. Whether ERKis are used alone or in combination, experience with BRAFi or MEKi has taught us to anticipate the emergence of ERKi resistance in tumours that show initial favourable responses; indeed, in vitro mutagenesis studies have already anticipated potential resistance mechanisms (Goetz et al., 2014) . Goetz et al. subjected the ERK1 and ERK2 cDNAs to random mutagenesis in E. coli, expressed them in BRAF V600E -positive A375 melanoma cells and selected them in the presence of the ERKi inhibitor VTX-11e, the MEKi trametinib or a MEKi+RAFi combination (trametinib + dabrafenib) (Goetz et al., 2014) . ERK1/2 mutations arising from selection in the ERKi VTX-11e were also cross-resistant to SCH772984 and were found to cluster within the ATP/drug binding pocket. Indeed, subsequent experiments demonstrated that these mutant ERK1/2 proteins were refractory to ERKi, strongly suggesting that they are "on target" resistance alleles that act by interfering with drug binding. In contrast, the ERK1/2 mutants arising from selection in RAFi/MEKi were distributed more widely throughout the ERK proteins; however, some mutations clustered in the αC helix and the common docking domain. Indeed, the ERK2 E322K mutation that is observed as a primary mutation in squamous cell carcinomas and sustains active ERK1/2 by preventing DUSP binding was amongst these mutants. Whilst these mutants were generated "artificially" rather than in cells they are clearly homing in on well understood vulnerabilities in protein kinases so it is highly likely that functionally similar mutations will arise in human tumours undergoing RAFi, MEKi or ERKi treatment and mitigation should be considered. In this context, it is notable that some of the ERK1/2 mutants arising during RAFi/MEKi selection were still sensitive to ERKi providing further support for intra-pathway combinations including, for example, alternate RAF/MEK and ERK dosing.
Conclusions
The clinical precedent of BRAFis and MEKis, both alone and in combination, together with pathway topology and the pivotal distributive role of ERK1/2 within the pathway provide strong rationale for developing inhibitors of ERK1/2. This has fuelled the development of a variety of novel, drug-like molecules and chemical probes that target ERK1/2. To date, attempts to develop allosteric inhibitors of ERK1/2 (dimerization inhibitors or substrate binding blockers) have not led to any drug-like molecules. Indeed, the utility of some of these probes as research tools is far from clear as many possess moieties such as electrophilic Michael acceptors that predispose to non-specific protein interactions. A critical control for these compounds will be to test their selectivity in biological systems by expressing non-drug binding mutants of ERK1/2; these should rescue biological effects if those effects are due to "on-target" ERK1/2 inhibition. To date only two covalent ERKis have been described but these provide strong proof-of-concept that this approach may work, whilst the successful development of covalent inhibitors of BTK, EGFR/ HER2 and EGFR T790M are compelling examples of what can be achieved.
The furthest advanced ERKis are a variety of "traditional" reversible ATP-competitive ERK1/2 inhibitors that are now undergoing various stages of clinical evaluation. These include molecules which are purely inhibitors of ERK1/2 catalytic activity and those which additionally are able to block MEK1/2-catalysed ERK1/2 T-E-Y phosphorylation. Intuitively, this latter "dual-mechanism" seems more attractive as it may limit the extent of ERK1/2 reactivation following feedback relief. However, the biological and clinical importance of this dual mechanism remains to be seen and it is notable that the lead compound selected from the SCH772984 programme did not retain the ability to inhibit the phosphorylation of ERK1/2 (Lim et al., 2016) . Finally, since the ATP-competitive ERKis do not have the exquisite selectivity, specificity even, of the allosteric MEKis, they are each likely to exhibit their own unique profile of "off target" activity against different subsets of kinases; this unique polypharmacology may enhance efficacy or may enhance toxicity and we await the results of ongoing trials with interest.
